Intragastric Balloons

A leading priority in modern medicine today is expanding options and improving access to cost-effective treatments for patients with obesity. Intragastric balloons (IGBs) are one such option, with increased effectiveness compared to pharmacotherapy and lifestyle and a lower rate of adverse events than bariatric surgery. IGBs are endoscopically placed or swallowed space-occupying devices in the stomach. Three IGB systems were approved in 2015 and 2016 by the FDA for use in the United States, and more devices are nearing approval. This paper reviews the common practices, efficacy, and adverse events associated with IGBs, as well as practice setup, management of common complications, and dietary advice for patients.